Although mutations in DNA are the best-studied source of neoantigens that determine
response to immune checkpoint blockade, alterations in RNA splicing within cancer cells could …

Understanding the tumor immune microenvironment (TIME) promises to be key for optimal
cancer therapy, especially in triple-negative breast cancer (TNBC). Integrating spatial …

Cancer immunoediting 1 is a hallmark of cancer 2 that predicts that lymphocytes kill more
immunogenic cancer cells to cause less immunogenic clones to dominate a population. …

Cancer immunotherapies, including adoptive T cell transfer, can be ineffective because tumors
evolve to display antigen-loss-variant clones. Therapies that activate multiple branches of …

The T-cell costimulatory receptors, CD28 and the inducible costimulator (ICOS), are required
for the generation of follicular B helper T cells (T FH ) and germinal center (GC) reaction. A …

Tryptophan catabolism by the enzymes indoleamine 2,3-dioxygenase 1 and tryptophan 2,3-dioxygenase
2 (IDO/TDO) promotes immunosuppression across different cancer types. The …

Paired single-cell RNA and T cell receptor sequencing (scRNA/TCR-seq) has allowed for
enhanced resolution of clonal T cell dynamics in cancer. Here, we report a scRNA/TCR-seq …

Intralesional therapy with oncolytic viruses (OVs) leads to the activation of local and systemic
immune pathways, which may present targets for further combinatorial therapies. Here, we …

The majority of JAK2 V617F -negative myeloproliferative neoplasms (MPNs) have disease-initiating
frameshift mutations in calreticulin (CALR), resulting in a common carboxyl-terminal …

Transcription factors ThPOK and Runx3 regulate the differentiation of “helper” CD4 + and “cytotoxic”
CD8 + T cell lineages respectively, inducing single positive (SP) T cells that enter …